Cannabis Law Report

JUNE 23, 2021

. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. About RYAH Group, Inc. RYAH Group, Inc. Forward-Looking Statements.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Forward-Looking Statements.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 105

Treatment Sleep Clinical Trials Data 105

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

JUNE 16, 2021

This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. Training will be provided within the research program for licensed practitioners to assess the safety of psychedelic medicines and to classify and report positive and adverse events.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Veriheal

MAY 30, 2023

But what if a safe and effective complementary plant-based treatment was widely available to alleviate cancer pain? of patients experience pain after curative treatment, while 66.4% in cancer patients undergoing anticancer treatment, 50.7% in those who had completed treatment, and as high as 66.7%

Medicine 98

Medicine Treatment Patients Data 98

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. Nurses are an integral part of any healthcare team, as they are tireless advocates for their patients and have unmatched organizational skills.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Cannigma

OCTOBER 21, 2021

Simon is not alone, one study reviewed online forum posts about cannabis and ADHD and found that 25% of posts indicated therapeutic benefits from this treatment – with statements like “While you are high … you will be able to focus much, much better than you normally would” and “(cannabis) helps me greatly with my ADHD.”

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. “Our billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

AUGUST 10, 2021

The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% It is an honour and privilege to be in the position to use novel psychedelic treatments to solve the complex puzzle that is chronic pain. These statements relate to future events or future performance. billion in 2030. 3 Psychol Res Behav Manag.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). PROGRAMME.and.ABSTRACTS. Patient-reported outcomes. Peer-reviewed analysis.

Cannabinoids 45

Cannabinoids Data Chronic Pain Sleep 45

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Cannabis Law Report

JULY 22, 2021

We believe that this will serve as a strong platform from which to deploy impactful alternative and psychedelic based treatment options,” stated Pouya Farmand, Chief Executive Officer of Levitee. About Levitee Labs. Levitee Labs is establishing itself as a leader in the integrative wellness space.

eCommerce 105

eCommerce Therapy Media Access 105

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. Diminishing efficacy of these receptors over time should be considered for proper treatment.

Events 48

Events THC Chronic Pain Sleep 48

The Blunt Truth

MARCH 10, 2020

CBD continues to flourish in the markets despite lack of federal regulations, and we’ve identified some significant events that indicate there’s no sign it’s stopping. Manufacturers are responsible for certifying records, including all product data, which includes, for example, information on formulation, labeling, and DEA Schedule.

CBD 99

CBD Topical Agriculture Hemp 99

Veriheal

SEPTEMBER 15, 2021

This is very important if we wish to see a day where cannabis has been removed from harsh drug scheduling and if we wish to see it become part of everyday treatment practices by professionals. . Non-Experimental Research: Observational study, or non-experimental research, focuses on analyzing data in its natural context.

Data 97

Data Collective Environment Cannabis 97

CannaTech

MAY 16, 2019

CannaTech Tel Aviv 2019 was an absolute sensation, and we are already looking to Cape Town for our next big event. Kassi is equipped for advanced data collection, offering accurate, real-time, shareable dispensing history, automated reminders and personal recommendations.

Data 13

Data Collective Consumption Treatment 13

Veriheal

JUNE 30, 2023

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The Summit found that cannabis does not enhance athletic performance.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

CannaMD

MARCH 8, 2020

The study authors arrived at this estimate based on a series of user-response surveys, with the notation that “given the substantial non-response [to the survey questions] these data are subject to response bias.”. Acknowledging the limited scope of data, few mechanisms of cardiovascular risk have emerge. a heart attack).

Patients 104

Patients Marijuana Research and Development Clinical Trials 104

Cannabis Law Report

JULY 28, 2021

Active research includes applications of machine learning and data mining as a member of the University of Alberta computational psychiatry group. His knowledge and insight will be paramount as we continue to navigate the development of DMT as a treatment for addiction disorders,” said Chief Executive Officer, Timothy Ko.

Research and Development 105

Research and Development Events Media Data 105

The Joint Blog

MARCH 3, 2021

The study is titled Medical cannabis for the treatment of fibromyalgia syndrome: A retrospective, open-label case series. in a cohort of 38 patients with treatment-resistant fibromyalgia. Thus, cannabinoids may be considered for FMS treatment, although several side effects may still occur. herbal cannabis, oil extracts, etc.)

Therapy 61

Therapy Hybrid Marijuana Research and Development 61

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Additionally, there were several instances in which cepharanthine displayed growth inhibition which was comparable or superior to current gold standard treatments, including colorectal, liver and skin cancers.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JANUARY 3, 2022

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

The Joint Blog

JANUARY 3, 2020

Marijuana-based medicines “might be effective and safe in the treatment of tics and comorbidities” in those with Gilles de la Tourette Syndrome, according to a new study published in the journal Cannabis and Cannabinoids Research and e-published by the National Institute of Health. ” Dosages of all CBM varied markedly.

Data 49

Data Treatment Marijuana Patients 49

Puff Puff Post

MARCH 10, 2020

.” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

SEPTEMBER 2, 2022

The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study.

Pharmaceutical 52

Pharmaceutical Legalization Marijuana Data 52

NORML

MAY 24, 2019

At the same time, the bill would redirect tax revenue from a legal industry towards various programs that redress harms from the War on Drugs, while also increasing and improving public education and treatment programs geared towards responsible use, reducing overdoses, and saving lives.

Marijuana 105

Marijuana Education Advocacy Legislation 105

SpeedWeed

MARCH 13, 2021

However, common treatments do not address the non-motor symptoms and can sometimes cause side effects including dyskinesia, an abnormality or impairment of voluntary movement. . As a result, many patients turn to complementary or alternative treatments for their disease. . One such alternative treatment is cannabis.

Patients 52

Patients Treatment Therapy Sleep 52

Illinois News Joint

APRIL 2, 2023

To find more cannabis-friendly events in Illinois, visit here. Below is Section 6z-112 of the State Finance Act that governs the distributions of the Cannabis Regulation Fund. For more Illinois cannabis industry news, visit here. For Illinois News Joint reviews, visit here. Expenditures for these purposes shall be subject to appropriations.

Education 98

Education Cannabis Collective Programs 98

Freedom Leaf

JANUARY 4, 2018

After months of development, my partner and I built and successfully launched the beta for our cannabis data-analytics software, Jade Insights. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making. ” JOHN KAGIA. ” OPHELIA CHONG.

Data 60

Data Policy Media Cannabis 60